Baloxavir (Xofluza) for Post-Exposure Prophylaxis of Influenza

Date: January 11, 2021 Issue #:  1615Summary:  The oral polymerase acidic endonuclease inhibitor baloxavir marboxil (Xofluza— Genentech) is now FDAapproved for post-exposure prophylaxis of influenza in patients ≥12 years old. Baloxavir was approved for treatment of acute uncomplicated influenza in patients ≥12 years old in 2018.1 Two neuraminidase inhibitors are FDA-approved for prophylaxis of influenza: oseltamivi r(Tamiflu, and generics) in patients ≥1 year old, and zanamivir(Relenza) in patients ≥5 years old.2 Unlike oseltamivir and zanamivir, baloxavir is not FDA-approved for pre-exposure prophylaxis of influenza during institutional or community outbreaks.
Source: The Medical Letter - Category: Drugs & Pharmacology Authors: Tags: baloxavir influenza Oseltamivir Relenza Tamiflu Xofluza Zanamivir Source Type: research